Medsensio
About us
By using smart technology and a patient centred approach, Medsensio aims to reduce the cost of chronic care and improve patient outcomes
2016
Tromsø 7
The initial work on our AI was started in 2016 as a collaboration between UiT The Arctic University of Norway and the population study Tromsø Study 7
2017
STUD-ENT
Medsensio received the first round of financing from the Norwegian Research Council in 2017
2020
Horizon 2020
In 2020 Medsensio and the PyXy.ai consortium are funded by the EU to develop a patient monitoring platform
2022
Launch
Medsensio platform for patient monitoring is officially launched in 2022 after receiving ISO 27001 certification
Roadmap
2023
CE Certification
The first AI algorithms for analysis of lung and heart sounds will be certified as medical device in 2023
2023
Aortic Stenosis AI
In collaboration with the University Hospital of Northern Norway, we will begin verification of our aortic stenosis detection algorithm in Q3-Q4 2023
2024
Disease Prediction
By Q4 2023 we will have our first disease prediction algorithms available for testing on our platform. In 2024, these algorithms will be verified and certified as medical device for the European and US market
2025
Autonomous AI
By 2025 Medsensio will release our autonomous decision support system that will provide expert level support and guidance for both patients and healthcare personnel.
2017
Tromsø 7
The initial work on our AI was started in 2016 as a collaboration between UiT The Arctic University of Norway and the population study Tromsø Study 7
2017
STUD-EN
Medsensio received the first round of financing from the Norwegian Research Council in 2017
2020
Horizon 2020
In 2020 Medsensio and the PyXy.ai consortium are funded by the EU to develop a patient monitoring platform
2022
Launch
Medsensio platform for patient monitoring is officially launched in 2022 after receiving ISO 27001 certification
Our background
Medsensio is a research- and science based company that started as spin-off from research under the Tromsø study 7 at UiT the Arctic University of Norway. We are an enthusiastic team of skilled clinicians, scientists, health data analysts, machine learning and computer engineers and entrepreneurs trying to improve patient's care with medical AI and integrated information flows.
Quality focus
Our primary focus is being a quality-assured manufacturer and provider of software, medical software and machine learning algorithms. Therefore, we direct attention at building relevant hardware partnerships and following standards for data management and sharing across platforms. Our information security system is certified according to ISO 27001:2017, and we are currently in the final implementation phase for quality management system following ISO 13485:2016.
Collaborations
Medsensio is open for collaboration with a wide range of partners. Our platform is built using a modular approach following the FHIR standard, allowing us to configure a product specifically for your need with minimal effort. We have experience supporting both clinical and research application.
Contact us to learn more about how we can help meet your needs.
Executive team
We are a dedicated and highly motivated team with complementary backgrounds in business, computer science and medicine, combining the right expertise to build solutions which will improve chronic patients' healthcare.
Medsensio was co-founded in 2017 by Anna Dranovska, Johan Ravn and Professor Lars Ailo Bongo from UiT. The startup was initially based on research results from the 7th edition of the population study in Tromsø.
In 2020, Medsensio and the PyXy.ai consortium was awarded funding by the European research and innovation fund, Horizon 2020. This allowed Medsensio to scale up the operations, adding Markus K. Johnsen to the executive team and adding more resources to the R&D teams.
Anna uses her background from business and innovation to oversee the management team, ensuring that all processes of the company are coordinated in a unified direction.
Anna Dranovska
Chief Executive Officer
Johan is responsible for the technological development of Medsensio's products. This involves compliance to regulations, information security and oversight of both AI and product engineering.
Johan Ravn
Chief Technology Officer
Markus adds clinical experience and medical knowledge to the executive team. He is responsible for ensuring that the company and product strategies are aligned to meet the needs of the medical industry.
Markus Kreutzer Johnsen
Chief Medical Officer
Ethical AI
As part of our commitment to delivering ethical AI, Medsensio is teaming up with the ENACT consortium in developing and testing a process for evaluating the ethical consideration of digital solutions.
ENACT (Ethical risks assessmeNt of Artificial intelligenCe in pracTice) is lead by Leonora Onarheim Bergsjø. The project group consists of Sintef Digital, Østfold University College Faculty of Teacher Education and Languages, Norwegian Open AI Lab at NTNU, Institute for Informatics at UiO, Center for e-health at UiA, University College London and Imperial College London.
Additional participating research networks are Norwegian Artificial Intelligence Research Consortium (NORA) and Innovationnetwork Cluster for Applied AI/Smart Innovation Norway, together with Norwegian Council for Digital Ethics (NORDE).
